A New Frontier in Cancer Treatment
summary
Claims a platform that engineers cancer cells with a synthetic promoter delivered by a non‑viral nanoplasmid so malignant cells "turn on" and produce either a PET‑visible epitope or a therapeutic cytokine. Development solves liver‑bias of standard LNPs and reports 98% activation in patient tumor samples vs ~13% for the original construct. Shown to light up multiple tumors in 60 kg pigs, to shrink human tumors in humanized mice to zero, and to enter phase 1–2 human trials within 1–2 years.
AI-written summary · about